Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.2 (
guanylate cyclase
)
8,497
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The nitric oxide-cyclic GMP pathway is still undefined regarding regulation of the release of hepatic lipase (
HTGL
). It was found that L-arginine (Arg) stimulated the release of
HTGL
activity from rat hepatocytes in a time- and dose-dependent manner. L-Arg-stimulated release of
HTGL
activity was inhibited by N-monomethyl-L-Arg, which is a nitric oxide synthase inhibitor. L-Arg markedly increased the cyclic GMP content of hepatocytes in the presence of a cyclic GMP phosphodiesterase inhibitor. Zaprinast. The release of the enzyme activity was also suppressed by methylene blue (a
guanyl cyclase
inhibitor) and KT5823 (a cyclic GMP-dependent protein kinase inhibitor). These results suggest that the stimulation of nitric oxide synthesis by L-Arg increases the release of
HTGL
activity due to processes associated with the elevation of cyclic GMP level, probably through an activation of protein kinase.
...
PMID:Stimulation of nitric oxide-cyclic GMP pathway by L-arginine increases the release of hepatic lipase from cultured rat hepatocytes. 891 15
